The Simons Foundation Autism Research Initiative (SFARI) has launched SPARKForAutism.org, a dynamic platform that is engaging thousands of individuals with autism spectrum disorder (ASD) and connecting them to researchers. By making all data accessible, SPARK seeks to increase our understanding of ASD and accelerate new supports and treatments for ASD.

No abstract

BackgroundAdolescents with autism spectrum disorder (ASD) spend more time using electronic screen media than neurotypical peers; preliminary evidence suggests that computer-assisted or Web-based interventions may be beneficial for social skills acquisition. The current generation of adolescents accesses the Internet through computers or phones almost daily, and Facebook is the most frequently used social media platform among teenagers. This is the first research study to explore the use of Facebook as a therapeutic tool for adolescents with ASD.ObjectiveTo study the feasibility and clinical impact of using a Web-based social platform in combination with social skills training for adolescents with ASD.MethodsThis pilot study enrolled 6 participants (all males; mean age 14.1 years) in an online social skills training group using Facebook. Data was collected on the participants’ social and behavioral functioning at the start and conclusion of the intervention. Outcome measures included the Social Responsiveness Scale-2, the Social Skills Improvement System Rating Scale, and the Project Rex Parent Survey. Participants were surveyed at the conclusion of the intervention regarding their experience.ResultsNo statistically significant differences in measurable outcomes were observed. However, the online addition of Facebook was well received by participants and their parents. The Facebook intervention was able to be executed with a careful privacy protocol in place and at minimal safety risk to participants.ConclusionsThe utilization of Facebook to facilitate delivery of social skills training for adolescents with ASD appears to be feasible, although the clinical impact of such an addition is still unclear. It is important to note that social difficulties of participants persisted with the addition of the online platform and participants still required assistance to engage with peers in an online environment. A Web-based intervention such as the one utilized in this study has the potential to reach a mass number of patients with ASD and could address disparities in access to in-person treatment services. However, the complexity and evolving nature of Facebook’s website and privacy settings leads to a number of unique online safety concerns that may limit its clinical utility. Issues encountered in our study support the development of an alternative and closed Web-based social platform designed specifically for the target audience with ASD; this platform could be a safer and more easily moderated setting for aiding in social skills development. Despite a small sample size with no statistically significant improvements of target symptoms, the use of electronic screen media as a therapeutic tool for adolescents with ASD is still a promising area of research warranting further investigation. Our study helps inform future obstacles regarding feasibility and safety.

Patients with autism spectrum disorder (ASD) are at high risk for comorbid major depressive disorder (MDD), which can severely impair functioning and quality of life. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique, which is Food and Drug Administration (FDA) cleared for the treatment of MDD in adults. Despite demonstrated efficacy in the treatment of depression, there are limited data on the use of rTMS in patients with ASD and comorbid MDD. We hypothesized that a standard rTMS protocol for MDD would reduce depressive symptoms for adults with ASD and MDD. Secondarily, we investigated whether this treatment would also reduce core ASD symptoms. Participants of 18–65 years old with ASD and MDD without any medication changes in the last month were eligible for this open‐label trial. Participants underwent 25 sessions of rTMS (figure‐of‐eight coil, 100–120% resting motor threshold, 10 Hz, 3,000 pulses per session) applied to the left dorsolateral prefrontal cortex. Thirteen participants enrolled in the study, with two withdrawing due to tolerability, and one excluded from analysis. Overall, side effects were mild and rTMS was well tolerated. The Hamilton rating scale for depression (HAM‐D17) improved 13.5 points (IQR 5–15), and 40% of participants achieved remission (HAM‐D17 ≤ 7) after rTMS treatment. Informant clinical scales of core symptoms of autism also suggested improvement with rTMS, though no change was observed by the participants themselves. Thus, this open‐label trial suggests that high‐frequency rTMS is well tolerated by adults with autism and MDD, with improvement in depressive symptoms and possible effects on core autism symptoms. Autism Res 2020, 13: 346–351. © 2020 International Society for Autism Research,Wiley Periodicals, Inc. Lay Summary This study evaluated the safety and effects of repetitive transcranial magnetic stimulation (rTMS) on depression and autism symptoms in individuals with both major depressive disorder and autism spectrum disorder. rTMS was well tolerated by the participants, depression improved with treatment, and family members' assessment of autism symptoms improved as well. This study supports the need for further work to evaluate rTMS in individuals who have both autism and depression.

No abstract

Outcomes assessment has become an important tool in assessing the quality of health care. To date, most quality initiatives have focused on adverse events, clinical processes, and/or cost variables. Considerably less attention has been paid to indices of clinical improvement, especially from a patient's perspective and in behavioral health settings. The relative inattention given to clinical improvement is attributable to a number of reasons, including (but not limited to) a lack of consensus regarding measures of improvement, few simple methods for data collection and analysis, and an inability to provide timely feedback. In this article, the authors describe a Web-based system designed to routinely collect quality-of-life ratings from patients in outpatient behavioral health clinics, allowing for real-time feedback at the patient levels regarding clinical improvement. The system also allows for administrative evaluation of overall clinic performance. The costs and benefits of this system are discussed.

No abstract

Background:The increase in prevalence of Autism Spectrum Disorder (ASD) has led to a corresponding surge in demand for novel, effective, and safe clinical interventions. Evidence-based treatment options for ASD are limited, resulting in a high utilization rate of complementary and alternative medicine (CAM) treatments in the ASD population. Yoga is a CAM practiced by over 20 million people in the United States, and multiple studies have investigated yoga as a possible effective treatment intervention for patients with ASD. Patients with ASD could potentially benefit from yoga either directly, through the targeting of core ASD symptoms, or indirectly through the improvement of commonly occurring co-morbid psychiatric conditions. Objective: To review the evidence for yoga as an effective treatment option for patients with ASD.Method: Using a variety of online databases, including PubMed, PsychINFO, Scopus, CINAHL, and Google Scholar, published studies meeting the authors' selection criteria were reviewed for evidence of improvement in core ASD and related symptoms in patients with ASD.Results: There is a paucity of studies published in peer-reviewed journals that met the search criteria. While each of the studies investigated the use of yoga with ASD subjects, they targeted a broad range of symptom clusters, and varied greatly in overall quality, methods, outcome measures, and results. Conclusion:Based on published studies, there is little current evidence that yoga improves core autism symptoms and co-morbid psychiatric symptoms in patients with ASD. However, there is a clear need for additional, larger randomized trials targeting both core ASD symptoms and co-morbid psychiatric conditions. Future clinical trials should utilize more uniform intervention methods, a standardized set of outcome measures, and blinded raters in order to determine whether yoga is indeed an evidence-based treatment option for patients with ASD.